| First Author | Wong CK | Year | 2018 |
| Journal | Diabetes | Volume | 67 |
| Issue | 3 | Pages | 412-422 |
| PubMed ID | 29217654 | Mgi Jnum | J:257516 |
| Mgi Id | MGI:6118032 | Doi | 10.2337/db17-0237 |
| Citation | Wong CK, et al. (2018) The p300 and CBP Transcriptional Coactivators Are Required for beta-Cell and alpha-Cell Proliferation. Diabetes 67(3):412-422 |
| abstractText | p300 (EP300) and CBP (CREBBP) are transcriptional coactivators with histone acetyltransferase activity. Various beta-cell transcription factors can recruit p300/CBP, and thus the coactivators could be important for beta-cell function and health in vivo. We hypothesized that p300/CBP contribute to the development and proper function of pancreatic islets. To test this, we bred and studied mice lacking p300/CBP in their islets. Mice lacking either p300 or CBP in islets developed glucose intolerance attributable to impaired insulin secretion, together with reduced alpha- and beta-cell area and islet insulin content. These phenotypes were exacerbated in mice with only a single copy of p300 or CBP expressed in islets. Removing p300 in pancreatic endocrine progenitors impaired proliferation of neonatal alpha- and beta-cells. Mice lacking all four copies of p300/CBP in pancreatic endocrine progenitors failed to establish alpha- and beta-cell mass postnatally. Transcriptomic analyses revealed significant overlaps between p300/CBP-downregulated genes and genes downregulated in Hnf1alpha-null islets and Nkx2.2-null islets, among others. Furthermore, p300/CBP are important for the acetylation of H3K27 at loci downregulated in Hnf1alpha-null islets. We conclude that p300 and CBP are limiting cofactors for islet development, and hence for postnatal glucose homeostasis, with some functional redundancy. |
